RCKT SEC Filing News — Rocket Pharmaceuticals, Inc.

Latest SEC filings for Rocket Pharmaceuticals, Inc. (RCKT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-06.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni…
Sector: Healthcare Industry: Biotechnology Market Cap: $245.9M CIK: 1281895
20
Total Filings
0
Bullish Classifications
7
Bearish Classifications
7
Insider Transactions
3
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for RCKT currently lean bearish. Of the 20 filing records displayed, 7 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
RCKT Filing Activity Snapshot 2026-08-11 — 2026-10-06
Insider Transactions (Form 4)
0 buys vs 7 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$256.5K
Wilson Martin · 2026-09-11
75,364 shares · Form 144
Form 144 Notices
10
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 7 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 7 filings in this group are Form 4s for Rocket Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 7 insider filings shown, the breakdown is 7 open-market sale. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×7
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-09-15

RCKT insider Wilson Martin (General Counsel) sold 75,364 shares (~$256.5K)

Wilson Martin, listed as General Counsel at ROCKET PHARMACEUTICALS, INC., reported an open-market sale of 75,364 RCKT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 75,364 $3.40 $256.5K
Filing: Form 4 (Insider Transaction) Insider: Wilson Martin (General Counsel) Shares: 75,364 Est. Value: $256.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-20

RCKT insider Wilson Martin (General Counsel) sold 631 shares (~$2.1K)

Wilson Martin, listed as General Counsel at ROCKET PHARMACEUTICALS, INC., reported an open-market sale of 631 RCKT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 631 $3.38 $2.1K
Filing: Form 4 (Insider Transaction) Insider: Wilson Martin (General Counsel) Shares: 631 Est. Value: $2.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-20

RCKT insider Shah Gaurav (CEO) sold 2,293 shares (~$7.8K)

Shah Gaurav, listed as CEO at ROCKET PHARMACEUTICALS, INC., reported an open-market sale of 2,293 RCKT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,293 $3.38 $7.8K
Filing: Form 4 (Insider Transaction) Insider: Shah Gaurav (CEO) Shares: 2,293 Est. Value: $7.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-17

RCKT insider Shah Gaurav (CEO) sold 2,837 shares (~$9.6K)

Shah Gaurav, listed as CEO at ROCKET PHARMACEUTICALS, INC., reported an open-market sale of 2,837 RCKT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,837 $3.38 $9.6K
Filing: Form 4 (Insider Transaction) Insider: Shah Gaurav (CEO) Shares: 2,837 Est. Value: $9.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-17

RCKT insider Wilson Martin (General Counsel) sold 3,493 shares (~$11.8K)

Wilson Martin, listed as General Counsel at ROCKET PHARMACEUTICALS, INC., reported an open-market sale of 3,493 RCKT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,493 $3.38 $11.8K
Filing: Form 4 (Insider Transaction) Insider: Wilson Martin (General Counsel) Shares: 3,493 Est. Value: $11.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

RCKT insider Stevens Christopher James (Chief Operating Officer) sold 36,658 shares (~$128.3K)

Stevens Christopher James, listed as Chief Operating Officer at ROCKET PHARMACEUTICALS, INC., reported an open-market sale of 36,658 RCKT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 36,658 $3.50 $128.3K
Filing: Form 4 (Insider Transaction) Insider: Stevens Christopher James (Chief Operating Officer) Shares: 36,658 Est. Value: $128.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

RCKT insider Chaudhuri Sarbani (See Remarks) sold 4,701 shares (~$16.4K)

Chaudhuri Sarbani, listed as See Remarks at ROCKET PHARMACEUTICALS, INC., reported an open-market sale of 4,701 RCKT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 4,701 $3.50 $16.4K
Filing: Form 4 (Insider Transaction) Insider: Chaudhuri Sarbani (See Remarks) Shares: 4,701 Est. Value: $16.4K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 10 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Rocket Pharmaceuticals, Inc. has 10 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-15

RCKT Form 144 filed for proposed insider sale by Militello John (6,897 shares) ~$22.7K

Militello John filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Militello John Shares: 6,897 Est. Value: $22.7K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-14

RCKT Form 144 filed for proposed insider sale by Militello John (6,857 shares) ~$22.7K

Militello John filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Militello John Shares: 6,857 Est. Value: $22.7K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-11

RCKT Form 144 filed for proposed insider sale by Wilson Martin (75,364 shares) ~$256.5K

Wilson Martin filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Wilson Martin Shares: 75,364 Est. Value: $256.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-11

RCKT Form 144 filed for proposed insider sale by Militello John (8,923 shares) ~$30.4K

Militello John filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Militello John Shares: 8,923 Est. Value: $30.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-18

RCKT Form 144 filed for proposed insider sale by Shah Gaurav (2,293 shares) ~$7.8K

Shah Gaurav filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shah Gaurav Shares: 2,293 Est. Value: $7.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-18

RCKT Form 144 filed for proposed insider sale by Wilson Martin (631 shares) ~$2.1K

Wilson Martin filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Wilson Martin Shares: 631 Est. Value: $2.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-18

RCKT Form 144 filed for proposed insider sale by Militello John (1,252 shares) ~$4.2K

Militello John filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Militello John Shares: 1,252 Est. Value: $4.2K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-13

RCKT Form 144 filed for proposed insider sale by Wilson Martin (3,493 shares) ~$11.8K

Wilson Martin filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Wilson Martin Shares: 3,493 Est. Value: $11.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-13

RCKT Form 144 filed for proposed insider sale by Shah Gaurav (2,837 shares) ~$9.6K

Shah Gaurav filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shah Gaurav Shares: 2,837 Est. Value: $9.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-11

RCKT Form 144 filed for proposed insider sale by Stevens Christopher James (36,658 shares) ~$128.3K

Stevens Christopher James filed a Form 144 with the SEC indicating intent to sell RCKT (ROCKET PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Stevens Christopher James Shares: 36,658 Est. Value: $128.3K
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Rocket Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-06

RCKT filed 8-K — material company event

ROCKET PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-15

RCKT filed 8-K — material company event

ROCKET PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-27

RCKT filed 8-K — material company event

ROCKET PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →

How we classify Rocket Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on RCKT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — RCKT SEC Filings

More Tools for RCKT

RCKT Full Stock Analysis RCKT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper RCKT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the RCKT stock analysis page.

RCKT Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer